SIGA vs SLN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SIGA presents a stark contrast between a pristine balance sheet and a collapsing operational core, evidenced by a Piotroski F-Score of 4/9 (Stable). While the company maintains zero debt and an exceptional current ratio of 11.83, the YoY revenue decline of -95.30% and an operating margin of -250.38% indicate a severe crisis in business continuity. The current price of $4.76 trades at a premium to both the Graham Number ($4.47) and the Intrinsic Value ($2.24), suggesting the stock is overvalued relative to its fundamentals. Technical trends are fully bearish, and the earnings track record shows a consistent failure to meet analyst expectations.
SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.
Compare Another Pair
Related Comparisons
SIGA vs SLN: Head-to-Head Comparison
This page compares SIGA Technologies, Inc. (SIGA) and Silence Therapeutics plc (SLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.